The net clinical benefit (NCB) of anticoagulation use in patients with atrial fibrillation (AF) appears to decrease with advancing age, and this decline can be attributed to competing mortality risk, as shown in a study.
Evolocumab treatment over 2.3 years does not seem to benefit atherosclerotic patients without multiple clinical risk factors or high genetic risk, and these individuals also have a low event rate. However, those with high genetic risk, irrespective of clinical risk, have a high event rate and receive large relative and absolute benefit from this therapy, thus alleviating such risk, according to a study presented at the 2019 Scientific Sessions of the American Heart Association.
High levels of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide can help identify patients at risk of adverse cardiovascular events, according to a study presented at the 2019 Scientific Sessions of the American Heart Association (AHA 2019).
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).